id	sid	eid	entity	type
dpc-1879	3	1	2022;12(2):e2022049	CARDINAL
dpc-1879	3	2	two	CARDINAL
dpc-1879	3	3	dario buononato1	PERSON
dpc-1879	3	4	gaetano licata1	PERSON
dpc-1879	3	5	alessio gambardella1	PERSON
dpc-1879	3	6	alina de rosa1	ORG
dpc-1879	3	7	calabrese1	PRODUCT
dpc-1879	3	8	1	CARDINAL
dpc-1879	3	9	university of campania luigi vanvitelli	ORG
dpc-1879	3	10	naples	GPE
dpc-1879	3	11	italy	GPE
dpc-1879	4	1	tildrakizumab	PERSON
dpc-1879	4	2	de rosa	PERSON
dpc-1879	4	3	calabrese	NORP
dpc-1879	4	4	g. tildrakizumab	PERSON
dpc-1879	4	5	two	CARDINAL
dpc-1879	6	1	2022;12(2):e2022049	CARDINAL
dpc-1879	6	2	july 22	DATE
dpc-1879	6	3	2021	CARDINAL
dpc-1879	6	4	april 2022	DATE
dpc-1879	7	1	2022	CARDINAL
dpc-1879	8	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-1879	12	1	dario buononato	PERSON
dpc-1879	12	2	md	GPE
dpc-1879	12	3	university of campania	ORG
dpc-1879	12	4	luigi vanvitelli	PERSON
dpc-1879	12	5	sergio pansini	PERSON
dpc-1879	12	6	5	CARDINAL
dpc-1879	12	7	napoli	GPE
dpc-1879	12	8	italy	GPE
dpc-1879	13	1	up to 30%	PERCENT
dpc-1879	14	1	asymmetric oligoarticular	PERSON
dpc-1879	15	1	interleukins-17	DATE
dpc-1879	17	1	2cases	CARDINAL
dpc-1879	17	2	1	CARDINAL
dpc-1879	18	1	first	ORDINAL
dpc-1879	18	2	45-year-old	DATE
dpc-1879	18	3	10 years	DATE
dpc-1879	20	1	9 months	DATE
dpc-1879	20	2	110	CARDINAL
dpc-1879	20	3	u/l	EVENT
dpc-1879	20	4	u/l	EVENT
dpc-1879	21	1	secukinumab	PERSON
dpc-1879	21	2	300 mg sc	QUANTITY
dpc-1879	21	3	monthly	DATE
dpc-1879	21	4	october 2018 to	DATE
dpc-1879	21	5	november 2019	DATE
dpc-1879	22	1	tildrakizumab	PERSON
dpc-1879	22	2	100 mg	QUANTITY
dpc-1879	22	3	every 12 weeks	DATE
dpc-1879	23	1	second	ORDINAL
dpc-1879	23	2	56-year-old	DATE
dpc-1879	23	3	15 years	DATE
dpc-1879	25	1	october 2019 to september 2020	DATE
dpc-1879	25	2	adalimumab	PERSON
dpc-1879	25	3	40 mg	QUANTITY
dpc-1879	25	4	every 2 weeks	DATE
dpc-1879	26	1	2	CARDINAL
dpc-1879	27	1	2022;12(2):e2022049	CARDINAL
dpc-1879	27	2	tildrakizumab	PERSON
dpc-1879	27	3	december 2020	DATE
dpc-1879	29	1	th17	PRODUCT
dpc-1879	30	1	ltb4	GPE
dpc-1879	30	2	1	CARDINAL
dpc-1879	32	1	tildrakizumab	PERSON
dpc-1879	33	1	2	CARDINAL
dpc-1879	35	1	1	CARDINAL
dpc-1879	36	1	nguyen ct	PERSON
dpc-1879	36	2	bloch y	PERSON
dpc-1879	36	3	składanowska k	PERSON
dpc-1879	36	4	sn	ORG
dpc-1879	37	1	clin immunol	PERSON
dpc-1879	38	1	2019;206:15-22	CARDINAL
dpc-1879	39	1	10.1016	CARDINAL
dpc-1879	42	1	2	CARDINAL
dpc-1879	42	2	boehncke wh	PERSON
dpc-1879	42	3	brembilla nc	PERSON
dpc-1879	42	4	nissen mj	PERSON
dpc-1879	42	5	guselkumab	PERSON
dpc-1879	42	6	first	ORDINAL
dpc-1879	43	1	rev clin immunol	PERSON
dpc-1879	44	1	2021;17(1):5-13	DATE
dpc-1879	45	1	10.1080/1744666x.2020.1857733	DATE
dpc-1879	46	1	33251833	DATE
dpc-1879	47	1	1	CARDINAL
dpc-1879	48	1	1	CARDINAL
dpc-1879	48	2	2	CARDINAL
dpc-1879	48	3	age, years 45	DATE
dpc-1879	48	4	56	CARDINAL
dpc-1879	48	5	adalimumab	PERSON